calcium dobesilate + ranibizumab

A combination therapy consisting of oral calcium dobesilate and intravitreal ranibizumab injections. This approach is primarily used for treating diabetic macular edema (DME) and macular edema secondary to branch retinal vein occlusion (BRVO). Calcium dobesilate is a vascular-protective drug that prevents oxidative stress and inflammation, protects blood vessels, and improves circulation by lowering blood viscosity, inhibiting platelet activity, and reducing capillary permeability. Ranibizumab is a VEGF inhibitor administered through intravitreal injections. The combination has shown to reduce the required number of intravitreal injections while maintaining or improving efficacy in terms of visual acuity and central macular thickness compared to ranibizumab monotherapy.